XM does not provide services to residents of the United States of America.
T
T

Teva


News

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports

Novo says Ozempic 'very likely' to be on 2027 Medicare negotiation list, Bloomberg News reports Sept 17 (Reuters) - Danish drugmaker Novo Nordisk NOVOb.CO expects its diabetes drug Ozempic will "very likely" be on the U.S. government's 2027 list of price negotiations, Bloomberg News reported on Tuesday citing a company executive . Part of 2022's Inflation Reduction Act allows Medicare to negotiate prices for prescription drugs that had been particularly expensive for the federal health program w
P
T

Baltimore to take drug distributors to trial over opioids

UPDATE 1-Baltimore to take drug distributors to trial over opioids Adds comment from Cencora in paragraph 4 By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Baltimore to take drug distributors to trial over opioids

CORRECTED-Baltimore to take drug distributors to trial over opioids Corrects headline and lead, adds paragraphs 4-5 to state that J&J settled before trial By Brendan Pierson Sept 16 (Reuters) - The city of Baltimore is scheduled to go to trial this week in its $11 billion lawsuit accusing drug distributors McKesson MCK.N and Cencora COR.N of fueling an epidemic of opioid addiction and overdose deaths.
T
W
M

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

UPDATE 1-Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial Adds comment from J&J in paragraph 6 By Brendan Pierson Sept 10 (Reuters) - Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
T
W
M

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial

Baltimore settles with Teva, Walgreens ahead of scheduled opioid trial By Brendan Pierson Sept 10 (Reuters) - Baltimore said on Tuesday that it has settled with Walgreens WBA.O over claims that the pharmacy operator fueled opioid addiction in the Maryland city, the latest in a series of settlements totaling $402.5 million ahead of a trial scheduled to begin next week.
T
W
M

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year

UnitedHealth to remove AbbVie's Humira from some US drug reimbursement lists next year By Patrick Wingrove Sept 10 (Reuters) - UnitedHealth Group UNH.N said on Tuesday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of Jan. 1, 2025, and recommend less expensive biosimilar versions of the medicine instead.
A
C
P
T

Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say

EXCLUSIVE-Teva faces EU fine for disparaging rival multiple sclerosis medicine, sources say Adds the European Commission comment, Teva did not immediately respond to request for comment, details By Foo Yun Chee BRUSSELS, Sept 10 (Reuters) - Teva TEVA.TA , the world's largest generic drugmaker, will be hit with an EU antitrust fine in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday
T

EU set to fine Teva for disparaging rival multiple sclerosis medicine, sources say

EXCLUSIVE-EU set to fine Teva for disparaging rival multiple sclerosis medicine, sources say BRUSSELS, Sept 10 (Reuters) - EU antitrust regulators are set to fine world No. 1 generic drugmaker Teva TEVA.TA in the coming weeks for disparaging a rival product to its blockbuster multiple sclerosis medicine Copaxone, people with direct knowledge of the matter said on Tuesday.
T

Column: Opioid plaintiffs' committee urges US appeals court to toss fee bid by shut-out law firms

Column: Opioid plaintiffs' committee urges US appeals court to toss fee bid by shut-out law firms The opinions expressed here are those of the author, a columnist for Reuters. By Alison Frankel Sept 9 (Reuters) - When it comes to calling dibs on $2.1 billion set aside for lawyers who contributed to settlements with nine major opioids defendants, the plaintiffs' lawyers in charge of the sweeping nationwide case are not kidding around.
T
M

US allows increased production of Takeda's ADHD drug and its generics to address shortage

CORRECTED-US allows increased production of Takeda's ADHD drug and its generics to address shortage Corrects headline and paragraph 1 to make clear Takeda's drug is not in shortage Sept 4 (Reuters) - The U.S. Drug Enforcement Administration has increased the production limit for Takeda Pharmaceutical's 4502.T ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the copies in the United States.
H
T

MedImpact Expands Access To Two Humira Biosimilars For New Patients

BRIEF-MedImpact Expands Access To Two Humira Biosimilars For New Patients Aug 27 (Reuters) - MedImpact Healthcare Systems: MEDIMPACT EXPANDS ACCESS TO TWO HUMIRA BIOSIMILARS FOR NEW PATIENTS MEDIMPACT: EXPANDING ACCESS TO SIMLANDI & ADALIMUMAB-ADAZ MEDIMPACT: MEMBER COPAY, DEDUCTIBLE, AND OTHER FACTORS WILL BE SAME FOR BIOSIMILARS & HUMIRA Source t
T

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year

Cigna to remove AbbVie's Humira from some drug reimbursement lists next year By Patrick Wingrove Aug 26 (Reuters) - Cigna CI.N said on Monday it will remove AbbVie’s ABBV.N blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey biosimilar versions of the medicine instead.
A
C
P
T

IT prods Indian shares towards record highs after Powell's dovish tilt

INDIA STOCKS-IT prods Indian shares towards record highs after Powell's dovish tilt Twelve of 13 major sectors logged gains Thirty-three of Nifty 50 stocks advance Small- and mid-caps rise 0.3% and 0.6%, respectively Market breadth skewed in favour of bulls Nifty 50 logs longest daily winning streak since July 2023 Updates to close By Bharath Rajeswaran BENGALURU, Aug 26 (Reuters) - Indian information technology stocks pushed domestic shares to within touching distance of a record high on Monday
T

India's Zydus Lifesciences falls as rival gets US FDA nod for generic drug

BUZZ-India's Zydus Lifesciences falls as rival gets US FDA nod for generic drug ** Shares of Zydus Lifesciences ZYDU.NS down 4.7%, top loser on Nifty pharma index .NIPHARM , which is mostly flat ** U.S. Food & Drug Administration over the weekend gave Teva Pharma TEVA.N approval of generic Asacol HD, used in treatment of some bowel diseases ** Zydus has enjoyed exclusivity in U.S.
C
T

Ozempic on Wall Street's list for 2027 Medicare drug negotiations

ANALYSIS-Ozempic on Wall Street's list for 2027 Medicare drug negotiations Novo Nordisk, Pfizer, GSK drugs likely to be in 2027 Medicare negotiations Most drugs already discounted, limited impact seen on Big Pharma Analysts expect price cuts to have bigger bite starting in 2028 By Michael Erman NEW YORK, Aug 23 (Reuters) - Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026 , Wall Street analysts are betting on a 2027 list that will include Novo N
G
P
T

Teva Pharma's listed shares up after company lifts 2024 forecasts

BUZZ-Teva Pharma's US-listed shares up after company lifts 2024 forecasts ** U.S.-listed shares TEVA.N of Israel-based Teva Pharmaceutical rise 4.5% to $17.2 premarket ** Company raises its FY forecasts as it benefits from strong demand for its cheaper generic medicines and branded treatment for Huntington's disease (HD) ** TEVA is banking on its b
T

Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary

Teva Pharmaceutical Industries Ltd reports results for the quarter ended in June - Earnings Summary Teva Pharmaceutical Industries Ltd TEVA.TA reported quarterly adjusted earnings of 61 cents​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of 56 cents. The mean expectation of four analysts for the quarter was for earnings of 57 cents per share.
T

Teva boosts forecasts as sales of generics, Huntington's disease drug jump

UPDATE 3-Teva boosts forecasts as sales of generics, Huntington's disease drug jump Adds details from conference call in paragraphs 4,5,6 and 7; analyst comment in paragraph 15, graphic By Bhanvi Satija and Michael Erman July 31 (Reuters) - Teva Pharmaceutical Industries TEVA.N raised its annual forecasts on Wednesday, banking on strong demand for its cheaper copycat medicines, including a GLP-1 generic, and branded treatment for Huntington's disease.
T

Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales

Teva Pharma lifts annual profit view on strong generic, Huntington's disease drug sales July 31 (Reuters) - Teva Pharmaceutical Industries TEVA.N raised its full-year profit forecast on Wednesday, banking on strength in its generic drug business and strong sales of its Huntington's disease drug. Teva now expects its profit for the full year 2024 to be between $2.30 and $2.50 per share, compared with its previous expectation of $2.20-$2.50 per share.
T

Teva Pharmaceutical Industries Ltd <TEVA.N> expected to post earnings of 55 cents a share - Earnings Preview

Teva Pharmaceutical Industries Ltd expected to post earnings of 55 cents a share - Earnings Preview Teva Pharmaceutical Industries Ltd TEVA.N , TEVA.K is expected to show a rise in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Tel Aviv-yafo Israel-based company is expected to report a 4.6% increase in revenue to $4.056 billion from $3.88 billion a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
T



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.